Acotec Scientific Holdings Limited (HKG:6669)

Market Cap	4.05B +94.3%
Revenue (ttm)	717.35M +20.7%
Net Income	132.63M +128.0%
EPS	0.44 +132.4%
Shares Out	313.39M
PE Ratio	29.39
Forward PE	23.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	406,000
Average Volume	325,300
Open	12.09
Previous Close	12.09
Day's Range	11.93 - 13.00
52-Week Range	6.29 - 15.47
Beta	0.17
RSI	57.50
Earnings Date	Mar 26, 2026

About HKG:6669

Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company’s products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee arteries ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2011
• Employees: 645
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6669

Financial Performance

In 2025, HKG:6669's revenue was 644.63 million, an increase of 20.72% compared to the previous year's 533.99 million. Earnings were 119.18 million, an increase of 127.97%.

Financial numbers in CNY